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1. AuNP	  Characterization	  
The	  most	  important	  physicochemical	  parameters	  of	  the	  gold	  nanoparticles	  (AuNP)	  used	  are	  already	  
presented	  in	  Table	  1	  in	  the	  main	  text.	  Here	  we	  additionally	  present	  the	  full	  UV-­‐Vis	  spectra	  (Figure	  S1)	  
and	  the	  size	  distribution	  histograms	  together	  with	  TEM	  images	  (Figure	  S2A-­‐E)	  of	  the	  AuNP.	  
	  
Figure	  S1:	  UV-­‐Vis	  spectra	  of	  the	  different	  sizes	  of	  the	  AuNP.	  
	  
In	  Table	  S1	  the	  physicochemical	  parameters	  and	  dose	  metrics	  are	   listed	  for	  the	   in	  vivo	   studies	  that	  
were	  compared	  to	  the	  cellular	  monolayers	  (CMLs).	  
	  
Table	  S1:	  Physicochemical	  parameters	  and	  dose	  metrics	  of	  AuNP	  that	  were	  used	  by	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Kreyling	  et	  al.	  [1]	  and	  Schleh	  et	  al.	  [2]	  
Source	   Diameter	  (nm)	   Dosea	  (ng/cm2)	   Surface	  functionalizationc	   ζ-­‐potential	  (mV)	  
Kreyling	  et	  al.	  [1]	  
1.4	   0.65	  ±	  0.10	   S-­‐TPP	  (SO3
-­‐)	   -­‐20.6	  ±	  0.5	  
2.8b	   0.20	  ±	  0.03	   TGA	  (COO-­‐)	   negative	  
5	   8.63	  ±	  0.50	   S-­‐TPP	  (SO3
-­‐)	   -­‐21.1	  ±	  1.4	  
18	   0.63	  ±	  0.05	   S-­‐TPP	  (SO3
-­‐)	   -­‐22.8	  ±	  3.1	  
80	   4.40	  ±	  0.15	   S-­‐TPP	  (SO3
-­‐)	   -­‐23.3	  ±	  1.6	  
Schleh	  et	  al.	  [2]	   20	   3.31	   n.a.d	   n.s.	  (-­‐40)e	  
a	  	  mean	  ±	  standard	  deviation	  (SD);	  Kreyling	  et	  al.	  [1]:	  based	  on	  a	  lung	  surface	  area	  of	  4000	  cm2;	  Schleh	  et	  al.	  [2]:	  based	  
on	  a	  particle	  weight	  of	  8	  x	  10-­‐17	  g	  (only	  deposited	  particles	  were	  considered).	  
b	  Kreyling	  et	  al.	  used	  negatively	  and	  positively	  (CA	  (NH3
+);	  dose:	  4.43±0.32	  ng/cm2)	  charged	  2.8	  nm	  large	  AuNP.	  Detailed	  
information	  was	  only	  provided	  by	  Kreyling	  et	  al.	  [1]	  for	  the	  negatively	  charged	  particles.	  However,	  the	  biodistribution	  
of	  both	  particle	  types	  normalized	  to	  the	  amount	  of	  translocated	  gold	  is	  practically	  identical.	  
c	  S-­‐TPP	  (SO3
-­‐)	  –	  sulfonated	  triphenylphosphine;	  TGA	  (COO-­‐)	  –	  thioglycolic	  acid.	  
d	  not	  applicable;	  Particles	  were	  produced	  with	  a	  spark	  ignition	  generator.	  
e	  not	  specified	  by	  Schleh	  et	  al.	  [2];	  However,	  Masereel	  et	  al.	  [3]	  reported	  that	  uncoated	  AuNP	  may	  have	  a	  zeta	  potential	  
of	  approximately	  -­‐40	  mV.	   	  




Figure	  S2:	  Size	  distribution	  histograms	  and	  TEM	  images	  of	  the	  2	  nm	  (A),	  7	  nm	  (B),	  18	  nm	  (C),	  46	  nm	  (D)	  
and	  80	  nm	  (E)	  large	  gold	  particles	  after	  ALICE	  exposure.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Number	  of	  analyzed	  particles:	  259	  (2	  nm),	  227	  (7	  nm),	  244	  (18	  nm),	  188	  (46	  nm)	  and	  161	  (80	  nm).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(shaded	  areas	  represent	  the	  limit	  of	  detection).	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2. CML	  Characterization	  
The	   laser	   scanning	   microscope	   (LSM)	   images	   of	   the	   CMLs	   after	   24	   and	   48	   hours	   at	   the	   air-­‐liquid	  
interface	   (ALI)	  are	  already	   illustrated	   in	   the	  main	  part	  of	   the	  paper.	  Here	  we	  additionally	  show	  the	  
images	  of	  the	  CMLs	  after	  72	  and	  96	  hours	  at	  the	  ALI	  (Figure	  S3A-­‐D),	  which	  corresponds	  to	  48	  and	  72	  
hours	  after	  exposure	  in	  the	  air-­‐liquid	  interface	  cell	  exposure	  (ALICE)	  system.	  
	  
Figure	  S3:	  LSM	  images	  of	  cytoskeletal	  F-­‐actin	  (green)	  and	  the	  cell	  nuclei	  (grey).	  Orthogonal	  view	  of	  the	  
A549	  CML	  (A)	  72	  and	  (B)	  96	  hours,	  and	  of	  the	  MLE-­‐12	  CML	  (C)	  72	  and	  (D)	  96	  hours	  at	  the	  ALI.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
After	  24	  hours	  at	  the	  ALI,	  the	  CMLs	  were	  exposed	  to	  100	  ng/cm2	  18	  nm	  AuNP.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Within	  the	  blue	  circle	  the	  top	  view	  on	  the	  CML	  is	  depicted.	  
	  
The	   integrity	  of	   the	  CMLs	  was	  tested	  by	  assessing	  the	  permeability	   to	  dextran,	  an	  approach	  that	   is	  
commonly	   used	   to	   evaluate	   the	   permeability	   of	   epithelial	   barriers	   [4-­‐7].	  We	   exposed	   the	   CMLs	   to	  
Blue	   Dextran	   and	   measured	   the	   translocation	   within	   two	   hours	   from	   the	   apical	   side	   to	   the	  
basolateral	   medium	   (Figure	   S4).	   A	   relative	   absorbance	   of	   1	   corresponds	   to	   a	   Blue	   Dextran	  
translocation	   that	   is	   equal	   to	   the	   translocation	   through	   an	   empty	   insert.	   As	   reference	   control,	  
16HBE14o-­‐	  human	  bronchial	  epithelial	  CMLs	  were	  used,	  which	  are	  known	  to	  form	  a	  tight	  barrier	  [8].	  
As	  positive	  control,	  the	  CMLs	  were	  additionally	  exposed	  to	  ethylenediaminetetraacetic	  acid	  (EDTA),	  
which	   causes	   the	   detachment	   of	   the	   CML	   from	   the	   membrane	   [9]	   and,	   hence	   increases	   the	  
translocation	  of	  Blue	  Dextran.	  As	  can	  be	  seen,	  the	  A549	  CML	  was	  as	  tight	  as	  the	  16HBE14o-­‐	  CML	  at	  
all	  time	  points.	  The	  MLE-­‐12	  CML	  was	  slightly	  more	  permeably	  than	  the	  reference	  control.	  However,	  a	  
significantly	   increased	   translocation	   of	   Blue	  Dextran	   through	   the	  A549/MLE-­‐12	   CMLs	   compared	   to	  
the	  16HBE14o-­‐	  CML	  was	  obsorved	  only	  for	  the	  MLE-­‐12	  CML	  after	  48	  hours	  at	  the	  ALI	  (p	  <	  0.01).	  The	  
addition	  of	  EDTA	  caused	  a	  significantly	  increased	  translocation	  of	  Blue	  Dextran	  from	  the	  apical	  side	  of	  
the	  CML	  to	  the	  basolateral	  medium	  for	  both	  cell	  types	  and	  at	  all	  time	  points	  (p	  <	  0.01;	  except	  MLE-­‐12	  
CMLs	   after	   96	   hours	   at	   the	   ALI:	   p	   <	   0.05).	   The	   increased	   translocation	   of	   Blue	   Dextran	   after	   the	  
addition	  of	  EDTA	  was	  less	  pronounced	  for	  the	  MLE-­‐12	  CMLs.	  This	  is	  probably	  due	  to	  the	  fact	  that	  the	  
membrane	  was	  additionally	  coated	  with	  Matrigel,	  which	  supports	  the	  attachment	  of	  the	  cells.	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Figure	  S4:	  Integrity	  of	  A549	  and	  MLE-­‐12	  CMLs	  at	  various	  time	  points	  at	  the	  ALI.	  The	  translocation	  of	  
Blue	  Dextran	  (2,000	  kDa)	  through	  the	  CMLs	  was	  compared	  to	  16HBE14o-­‐	  CMLs	  (reference	  control)	  and	  
CMLs	  additionally	  exposed	  to	  EDTA	  (positive	  control).	  (data	  are	  expressed	  as	  mean±SD,	  n=3	  CMLs;	  
┌─┐	  indicates	  the	  significance	  level	  between	  two	  measurements	  °	  no	  significant	  difference,	  significant	  
difference:	  *	  p	  <	  0.05,	  **	  p	  <	  0.01).	  
Transepithelial	  electrical	  resistance	  (TEER)	  measurements	  were	  carried	  out	  to	  evaluate	  the	  integrity	  
of	  the	  CMLs	  (Figure	  S5).	  Both	  cell	   types	  show	  a	  very	  similar	  TEER	  time	  course,	  with	  a	  slightly	   lower	  
resistance	  for	  MLE-­‐12	  CMLs.	  In	  general,	  the	  TEER	  of	  the	  CMLs	  increased	  especially	  during	  the	  first	  24	  
hours	  after	  seeding	  and	  at	  the	  ALI,	  respectively.	  A	  steady	  rise	  in	  the	  TEER	  can	  also	  be	  observed	  from	  
day	  9	  onwards.	  This	  rise	  is	  associated	  with	  the	  formation	  of	  a	  second	  cellular	  layer	  (Figure	  S3),	  which	  
develops	  when	  the	  CMLs	  are	  longer	  than	  48	  hours	  at	  the	  ALI.	  Exposure	  to	  AuNP	  in	  the	  ALICE	  did	  not	  
significantly	  change	  the	  TEER	  of	  A549	  and	  MLE-­‐12	  CMLs	  24,	  48	  and	  72	  hours	  post-­‐exposure.	  
	  
Figure	  S5:	  The	  TEER	  of	  the	  A549	  and	  MLE-­‐12	  CMLs	  over	  time	  and	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
influence	  of	  exposure	  to	  100	  ng/cm2	  of	  18	  nm	  large	  AuNP	  at	  day	  8.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(data	  are	  expressed	  as	  mean±SD,	  n=5	  CMLs;	  significant	  difference:	  *	  p	  <	  0.05).	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3. Translocation	  Kinetics	  
Based	  on	  the	  number	  of	  cells/cm2	  (obtained	  from	  the	  LSM	  images)	  we	  estimated	  roughly	  the	  number	  
of	  nanoparticles	  (NPs)	  per	  cell	  that	  settle	  on	  the	  CMLs	  in	  the	  ALICE	  system.	  The	  number	  of	  AuNP	  per	  
cell	  for	  the	  different	  particle	  sizes	  and	  doses	  are	  summarized	  in	  Table	  S2.	  
Table	  S2:	  Estimation	  of	  the	  number	  of	  NPs	  per	  cell	  that	  settle	  on	  the	  CMLs	  in	  the	  ALICE	  system	  
AuNP	  Size	  (nm)	   Dose	  (ng/cm2)	  
#	  NPs/cell	  
A549	  CML	   MLE-­‐12	  CML	  
2	   100	   2,700,000	   2,100,000	  
7	   100	   62,000	   49,000	  
18	  
25	   1’100	   850	  
50	   2,200	   1,700	  
100	   4,400	   3,400	  
150	   6,500	   n.a.a	  
200	   8,700	   6,800	  
46	   100	   220	   170	  
80	   100	   42	   33	  
a	  not	  applicable	  
	  
In	  Figure	  S6,	  the	  gold	  distribution	  between	  the	  surface	  liquid,	  the	  cell	  monolayer	  and	  the	  basolateral	  
medium	  is	  shown	  for	  both	  cell	  types	  (A549	  and	  MLE-­‐12)	  and	  all	  incubation	  time	  periods	  (Figure	  S6A),	  
particle	   sizes	   (Figure	   S6B)	   and	   doses	   (Figure	   S6C).	   The	   translocation	   of	   AuNP	   to	   the	   basolateral	  
medium	  and	  the	  time-­‐dependent	  disposition	  is	  already	  extensively	  discussed	  in	  the	  main	  part	  of	  the	  
paper.	  The	  results	  for	  the	  size-­‐dependent	  disposition	  (Figure	  S6B)	  also	  show	  a	  larger	  fraction	  of	  gold	  
in	  the	  surface	  liquid	  of	  MLE-­‐12	  CMLs	  compared	  to	  A549	  CMLs,	  which	  is	  most	  likely	  linked	  to	  a	  higher	  
surface	   liquid	   height	   in	   MLE-­‐12	   CMLs.	   With	   decreasing	   particle	   size	   this	   difference	   becomes	   less	  
pronounced,	  which	  can	  be	  attributed	   to	   the	   fact	   that	   smaller	  particles	  can	  pass	  easier	   through	   the	  
CML.	   The	   dose-­‐dependent	   disposition	   (Figure	   S6C)	   is	   very	   much	   the	   same	   for	   all	   doses	   in	   both	  
particle	  types,	  with	  the	  exception	  of	  the	  decreased	  translocation	  in	  A549	  CMLs	  at	  a	  dose	  larger	  than	  
100	  ng/cm2.	  Also	  here,	  one	  can	  see	  the	  larger	  fraction	  of	  gold	  in	  the	  surface	  liquid	  of	  MLE-­‐12	  CMLs	  as	  
comparted	  to	  A549	  CMLs.	  
	   	  




Figure	  S6:	  Disposition	  of	  AuNP	  and	  ionic	  gold	  in	  the	  transwell	  chamber	  system	  for	  A549	  and	  MLE-­‐12	  
CMLs.	  (A)	  18	  nm	  AuNP	  at	  an	  exposure	  dose	  of	  100	  ng/cm2	  varying	  with	  time.	  (B)	  An	  exposure	  dose	  of	  
100	  ng/cm2	  AuNP	  after	  24	  hours	  for	  various	  particle	  sizes.	  (C)	  18	  nm	  AuNP	  after	  24	  hours	  for	  various	  
doses.	  The	  results	  of	  the	  translocated	  fraction	  (green	  areas)	  are	  presented	  in	  more	  detail	  in	  Figure	  5.	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In	   Figure	   S7A-­‐E,	   transmission	   electron	  microscopy	   (TEM)	   images	   of	   the	   A549	   CML	   24	   hours	   after	  
exposure	   to	   2,	   7	   or	   46	   nm	   large	   AuNP	   are	   depicted.	   As	   already	   discussed	   in	   the	  main	   text,	   after	  
exposure	  of	  the	  CML	  to	  2	  nm	  AuNP	  we	  could	  observe	  only	  one	  large	  agglomerate	  (ca.	  300	  nm),	  which	  
is	  shown	  in	  Figure	  S7B.	  Single	  particles	  or	  even	  small	  agglomerates	  did	  not	  have	  enough	  contrast	  to	  
be	  distinguished	  from	  the	  background.	  However,	  this	  indicates	  that	  the	  2	  nm	  AuNP	  were	  also	  mainly	  
present	   as	   single	   particles	   or	   very	   small	   agglomerates.	   The	   disposition	   of	   the	   7	   and	   46	   nm	   AuNP	  
within	   the	   CML	   was	   very	   similar	   to	   the	   18	   nm	   large	   particles	   (Figure	   8).	   The	   AuNP	   were	   mainly	  
present	   as	   single	   particles	   or	   as	   small	   agglomerates	   and	   freely	   distributed	   within	   the	   cytoplasm	  
(Figure	  S7B-­‐D)	  and	  next	  to	  the	  cell	  nucleus	  (Figure	  S7E).	  Particles	  in	  vesicles	  were	  not	  observed.	  
	  
	  
Figure	  S7:	  TEM	  images	  of	  intracellular	  particles	  in	  the	  A549	  CML.	  Agglomerates	  of	  (A)	  2	  nm	  and	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(B,C,D)	  7	  nm	  AuNP	  in	  the	  cytoplasm	  and	  (E)	  46	  nm	  AuNP	  in	  and	  next	  to	  the	  cell	  nucleus.	  24	  hours	  after	  
exposure	  to	  100	  ng/cm2	  AuNP	  in	  the	  ALICE	  system.	  The	  arrows	  are	  pointing	  towards	  the	  particles.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(all	  images	  without	  lead	  citrate	  and	  uranyl	  acetate	  staining).	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4. PBPK	  Modeling	  
4.1. PBPK	  Model	  Methodology	  and	  Parameterization	  
Our	   recently	   presented	   physiologically	   based	   pharmacokinetic	   (PBPK)	   model	   on	   titanium	   dioxide	  
(TiO2)	  NPs	  [10]	  was	  used	  for	  the	  simulation	  of	  the	  absorption,	  distribution,	  metabolism	  and	  excretion	  
(ADME)	  of	  AuNP.	  A	  detailed	  discussion	  of	  the	  model	  methodology	  can	  be	  found	  in	  Bachler	  et	  al.	  [10].	  
Here	   we	   will	   give	   just	   a	   brief	   overview	   on	   the	   model	   concept	   and	   the	   modifications	   that	   were	  
implemented	  for	  AuNP.	  
4.1.1. Absorption	  
In	  the	  AuNP	  PBPK	  model,	  only	  the	  absorption	  of	  AuNP	  after	  inhalation	  and	  instillation	  are	  considered	  
(no	   dermal	   or	   intestinal	   uptake).	   To	   this	   end,	   two	   sub-­‐compartments	   were	   added	   to	   the	   lung	  
compartment	  of	  the	  PBPK	  model:	  the	  lung	  deposition	  compartment	  and	  the	  lung	  deposition	  storage	  
compartment	  (Figure	  2).	  The	  inhaled/instilled	  AuNP	  are	  added	  to	  the	  lung	  deposition	  compartment.	  
From	   this	   compartment,	   the	   particles	   are	   then	   either	   translocated	   to	   the	   blood	   or	   to	   the	   lung	  
deposition	  storage	  compartment.	  Since	  the	   in	  vivo	  data	  that	  was	  used	  to	  determine	  the	  pulmonary	  
absorption	   is	   only	   available	   for	   the	   first	   24	  hours	   after	   exposure	   [1],	   it	   is	   currently	   not	   possible	   to	  
model	   the	   long-­‐term	  behavior	   (e.g.	  permanent	   storage,	  mucociliary	   clearance,	   translocation	   to	   the	  
blood	  circulation)	  of	  the	  AuNP	  in	  the	   lung	  deposition	  storage	  compartment.	  Hence,	  at	  the	  moment	  
the	  lung	  deposition	  storage	  compartment	  is	  modeled	  as	  a	  sink	  for	  AuNP.	  For	  the	  simulations	  that	  are	  
presented	   in	   this	   work	   this	   uncertainty	   about	   the	   long-­‐term	   behavior	   is	   of	   minor	   importance,	  
because	  the	  maximum	  simulated	  time	  is	  72	  hours.	  However,	  as	  indicated	  by	  our	  in	  vitro	  experiments,	  
in	  addition	  to	  the	  very	  fast	  translocation	  within	  the	  first	  couple	  of	  hours	  after	  exposure,	  there	  might	  
be	  a	  slow	  translocation	  of	  preliminarily	  stored	  AuNP	  from	  lung	  cells	  to	  the	  blood	  circulation,	  which	  
becomes	   significant	   after	   2-­‐3	   days.	   Hence,	   for	   long-­‐term	   simulations	   with	   the	   PBPK	   model	   such	  
kinetics	  have	  to	  be	  considered	  and	  possibly	  added	  to	  the	  model.	  
4.1.2. Distribution	  
The	  biodistribution	  of	  TiO2	  NPs	  was	  modeled	  according	  to:	  	  
• their	  ability	  to	  cross	  the	  capillary	  wall	  of	  the	  organs	  
• the	  phagocytosis	  capability	  by	  the	  mononuclear	  phagocyte	  system	  (MPS)	  
However,	  for	  the	  distribution	  of	  NPs	  to	  the	  MPS	  compartments	  (i.e.	  in	  the	  liver,	  lung	  and	  spleen)	  we	  
determined	  a	  threshold	  concentration	  of	  NPs	  in	  the	  blood	  that	  is	  necessary	  to	  trigger	  the	  uptake	  of	  
NPs	  by	  these	  compartments	  [10,	  11].	  In	  the	  in	  vivo	  studies	  that	  are	  presented	  in	  this	  work	  [1,	  2]	  the	  
concentrations	  of	  NPs	   in	   the	  blood	  are	  below	   this	   threshold.	  Hence,	   the	  MPS	   compartments	  were	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excluded	   in	   the	  AuNP	  PBPK	  model.	  Furthermore,	   in	   the	  TiO2	  NPs	  PBPK	  model,	  compartments	  were	  
implemented	  for	  the	  skin,	  intestines,	  stomach	  and	  bones.	  These	  organs/tissues	  were	  not	  individually	  
evaluated	  by	  Kreyling	  et	  al.	  [1],	  but	  were	  part	  of	  the	  “Remainder”	  compartment.	  Consequently,	  to	  be	  
in	   accordance	   with	   the	   in	   vivo	   data,	   these	   four	   compartments	   were	   merged	   with	   the	   remainder	  
compartment	  of	  the	  PBPK	  model.	  
The	  translocation	  rate	  from	  the	  blood	  to	  the	  organs	  was	  determined	  for	  the	  transcapillary	  pathway,	  
with	  the	  following	  equation:	  
𝑘!"#$%_!"##$_!"#$% =   b!"#$%_!"#$%&#%_!"#$% ∗   !!"#$%_!"##$!!"##$ 	   (	  S1	  )	  
where	   btrans_constant_organ	   [-­‐]	   represents	   the	   translocation	   constants	   for	   NPs	   which	   depend	   on	   the	  
capillary	  wall	  type	  (CT)	  of	  the	  organ	  and	  were	  taken	  from	  the	  TiO2	  NPs	  PBPK	  model,	  Qorgan_blood	  [L/min]	  
is	  the	  flux	  of	  blood	  through	  the	  organ	  and	  Vblood	  [L]	  is	  the	  total	  blood	  volume	  in	  the	  body.	  The	  CTs	  and	  
the	  corresponding	  btrans_constant_organ	  values	  can	  be	  found	  in	  Table	  S4	  and	  Table	  S5,	  respectively.	  
In	   the	   TiO2	   NPs	   PBPK	   model,	   also	   compartments	   are	   present	   that	   describe	   the	   deposition	   and	  
temporary	  storage	  of	  TiO2	  NPs	  in	  the	  different	  organs.	  However,	  since	  these	  kinetics	  only	  play	  a	  role	  
in	   simulations	   that	  are	   longer	   than	  one	  week,	   these	  compartments	  were	  also	   left	  out	   in	   the	  AuNP	  
PBPK	  model	  (maximum	  simulation	  time	  is	  three	  days).	  However,	  for	  long-­‐term	  simulations	  with	  the	  
PBPK	  model	  such	  kinetics	  have	  to	  be	  considered	  and	  possibly	  added	  to	  the	  model.	  
4.1.3. Metabolism	  
Like	   TiO2	   NPs,	   AuNP	   are	   very	   stable	   and	   do	   not	   dissolve	   under	   in	   vivo	   conditions	   [1,	   12].	   Hence,	  
dissolution	  kinetics	  were	  not	  implemented.	  
Furthermore,	   as	   any	   nanoparticle	   that	   comes	   into	   contact	   with	   a	   biological	   medium,	   AuNP	   are	  
immediately	   binding	   proteins	   to	   their	   surfaces	   [13].	   This	   protein	   corona	   guides	   the	   excretion	   and	  
biodistribution	   of	   NPs	   [14].	   For	   silver	   NPs,	   we	   could	   already	   show	  with	   the	   PBPK	  model	   that	   the	  
surface	  of	  the	  particles	  is	  only	  of	  minor	  importance	  for	  the	  simulation	  of	  the	  biodistribution	  [11].	  This	  
finding	  is	  further	  supported	  by	  the	  study	  of	  Kreyling	  et	  al.	  [1],	  who	  could	  show	  that	  for	  2.8	  nm	  AuNP	  
with	   a	   positive	   (NH3+)	   or	   negative	   (COO-­‐)	   zeta	  potential,	   an	   identical	   biodistribution	  was	  observed.	  
Solely	   the	   gold	   concentrations	   in	   the	   kidneys	   are	   significantly	  different	   (student’s	   t	   test:	   p	   <	  0.05).	  
However,	  the	  particles	  have	  a	  diameter	  that	  is	  close	  to	  the	  cut-­‐off	  size	  for	  the	  renal	  excretion	  of	  NPs	  
(ca.	  5	  nm)	  [15]	  and,	  hence,	  slight	  differences	  in	  the	  size	  distribution	  can	  strongly	  influence	  the	  uptake	  
of	  NPs	  by	  the	  kidneys	  and	  the	  renal	  excretion	  of	  NPs.	  Thus,	  it	  was	  assumed	  that	  the	  formed	  protein	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corona	   is	   comparable	   between	   the	   different	   types	   of	   AuNP	   and	   consequently	   surface-­‐dependent	  
kinetics	  were	  also	  not	  considered	  (as	  it	  was	  also	  done	  in	  the	  TiO2	  NPs	  PBPK	  model).	  
4.1.4. Excretion	  
The	  same	  biliary	  and	  urinary	  excretion	  rates	  as	  in	  the	  TiO2	  NPs	  PBPK	  model	  were	  used.	  
4.1.5. Parameterization	  
As	  discussed	  above,	  the	  structure	  and	  parameters	  of	  the	  AuNP	  PBPK	  model	  were	  taken	  largely	  from	  
our	  recent	  publication	  on	  TiO2	  NPs	  [10].	  The	  assumptions	  and	  parameters	  for	  the	  AuNP	  PBPK	  model	  
are	  summarized	   in	  Table	  S3-­‐S7.	  Hence,	   for	   the	  AuNP	  PBPK	  model	  only	   three	  parameters	  had	  to	  be	  
determined:	   the	   translocation	   rate	   from	   the	   organs	   to	   the	   blood,	   the	   translocation	   rate	   of	   the	  
deposited	  AuNP	  to	  the	  blood	  and	  the	  storage	  rate	  of	  the	  deposited	  AuNP	  in	  the	  lung.	  To	  this	  end,	  the	  
in	  vivo	  data	  after	  instillation	  of	  18	  nm	  large	  AuNP	  from	  Kreyling	  et	  al.	  [1]	  was	  used.	  	  
The	  translocation	  rate	  from	  the	  organs	  to	  the	  blood	  was	  increased	  compared	  to	  the	  TiO2	  NPs	  PBPK	  
model	  to	  consider	  the	  lower	  retention	  time	  of	  AuNP	  in	  the	  organs	  as	  compared	  to	  TiO2	  NP.	  This	  was	  
done	  by	  increasing	  the	  kinetic	  rate	  manually	  until	  the	  comparison	  of	  the	  in	  vivo	  data	  of	  Kreyling	  et	  al.	  
[1]	  to	  the	  results	  of	  the	  PBPK	  model	  showed	  a	  good	  conformity	  (Figure	  S8).	  	  
The	   lung	   storage	   and	   translocation	   rate	   (for	   the	   18	   nm	  particle)	  were	   fitted	   so	   that	   the	   lung	   gold	  
levels	  (80±14%	  dose/g	  organ)	  and	  the	  translocation	  fraction	  one	  hour	  after	  exposure	  (0.32±0.083%,	  
Figure	  S9)	  matched	  the	  in	  vivo	  data,	  respectively.	  It	  is	  important	  to	  mention	  that	  Kreyling	  et	  al.	  [1]	  did	  
not	  determine	  the	  biliary	  excretion	  of	  AuNP,	  due	  to	  the	  inability	  to	  distinguish	  biliary	  excreted	  AuNP	  
from	  AuNP	  cleared	  via	  the	  mucociliary	  route.	  Hence,	  the	  amount	  of	  translocated	  AuNP	  is	  decreasing	  
with	  time	   in	  the	  data	  of	  Kreyling	  et	  al.	   (Figure	  S9).	  With	  the	  PBPK	  model	   it	   is,	  however,	  possible	  to	  
distinguish	  AuNP	  excreted	  via	   the	  biliary	   route	   from	  AuNP	  cleared	  via	   the	  mucociliary	   route.	  Thus,	  
the	  in	  vivo	  data	  was	  adjusted	  with	  the	  PBPK	  model	  for	  the	  biliary	  excretion	  of	  AuNP,	  so	  that	  the	  total	  
translocation	   of	   AuNP	   through	   the	   air-­‐blood	   barrier	   for	   the	   data	   of	   Kreyling	   et	   al.	   could	   be	  
determined	  (Figure	  S9).	  
The	  lung	  translocation	  rates	  for	  the	  other	  particle	  sizes	  (i.e.	  2,	  7,	  46	  and	  80	  nm)	  were	  fitted	  with	  the	  
adjusted	   translocation	   fractions	   24	   hours	   post-­‐exposure	   from	   Kreyling	   et	   al.	   [1]	   (Figure	   5B).	   The	  
adjustment	  of	  the	  translocation	  fractions	  24	  hours	  post-­‐exposure	  was	  carried	  out	  by	   increasing	  the	  
translocation	   fractions	   with	   a	   factor	   of	   3.9,	   which	   was	   determined	   for	   18	   nm	   AuNP	   as	   described	  
above.	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Figure	  S8:	  Results	  of	  the	  PBPK	  model	  calibration	  with	  the	  data	  of	  Kreyling	  et	  al.	  [1]	  at	  different	  time	  
points	  after	  instillation	  of	  18	  nm	  AuNP	  in	  the	  rat	  lung	  (*in	  %	  dose;	  data	  are	  expressed	  as	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
mean±SD,	  n=4	  (rats)	  and	  n=1000	  iterations	  (PBPK	  model)).	  
	  
	  
Figure	  S9:	  Comparison	  of	  the	  translocation	  fractions	  through	  the	  air-­‐blood	  barrier	  of	  Kreyling	  et	  al.	  [1]	  
(light	  blue)	  and	  the	  PBPK	  model	  (18	  nm	  AuNP	  instillation	  in	  rat	  lung,	  dark	  blue).	  With	  the	  PBPK	  model	  it	  
was	  further	  possible	  to	  consider	  the	  biliary	  excretion	  of	  AuNP	  and,	  hence,	  to	  determine	  the	  total	  
translocation	  of	  AuNP	  across	  the	  air-­‐blood	  barrier	  (red,	  data	  are	  expressed	  as	  mean±SD,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
n=4	  (rats)	  and	  n=1000	  iterations	  (PBPK	  model)).	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4.2. Additional	  Results	  
In	  Figure	  S10,	  the	  comparison	  of	  the	  gold	  levels	  in	  the	  lung	  between	  the	  measured	  levels	  by	  Kreyling	  
et	  al.	  [1]	  and	  the	  predicted	  levels	  by	  the	  PBPK	  model	  are	  depicted.	  	  
	  
Figure	  S10:	  Comparison	  of	  the	  PBPK	  model	  to	  biokinetic	  data	  of	  female	  Wistar-­‐Kyoto	  rats	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
24	  hours	  after	  intratracheal	  instillation	  of	  various	  sizes	  of	  AuNP	  [1]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(data	  are	  expressed	  as	  mean±SD,	  n=4	  (rats)	  and	  n=1000	  iterations	  (PBPK	  model)).	  
The	   size-­‐dependent	   translocation	  kinetics	  of	   gold	  particles	   through	   the	  air-­‐blood	  barrier	  of	  Wistar-­‐
Kyoto	   rats	   are	   shown	   in	   Figure	   S11.	   The	   curves	   presented	   are	   the	   same	   as	   in	   Figure	   5B,	   but	  
complemented	  by	  the	  translocation	  fraction	  for	  200	  nm	  gold	  particles	  that	  was	  reported	  by	  Kreyling	  
et	  al.	  [1].	  The	  adjusted	  translocation	  fraction	  for	  200	  nm,	  however,	  was	  determined	  with	  a	  decreased	  
translocation	   rate	   from	   the	   blood	   to	   the	   liver	   and	   a	   decreased	   biliary	   excretion	   rate,	   because	   the	  
PBPK	  model	   is	   only	   applicable	   for	   particles	   up	   to	   150	  nm	   [11],	   based	  on	   the	  pore	   size	   of	   the	   liver	  
capillaries	   [16].	   For	  particles	   above	   this	   size	   limit	   it	  may	  be	  more	  difficult	   to	  pass	   the	  pores	  of	   the	  
capillary	  wall	  of	  the	  liver	  and	  it	  can	  be	  expected	  that	  larger	  particles	  are	  not	  that	  easily	  transported	  to	  
the	  liver	  tissue	  and	  are	  hardly	  excreted	  via	  the	  biliary	  pathway.	  This	   is	  basically	  the	  same	  threshold	  
phenomenon	  that	  can	  be	  seen	  in	  the	  kidneys	  for	  AuNP	  that	  are	  larger	  than	  5	  nm.	  Once	  the	  particles	  
are	  larger	  than	  the	  pore	  size	  of	  the	  kidney	  capillaries,	  they	  are	  transported	  at	  a	  much	  lower	  rate	  to	  
the	  kidneys	  and	  urine	   (Figure	  9).	  Thus,	   for	  200	  nm	   large	  gold	  particles	   the	  same	   liver	   translocation	  
rate	   and	   biliary	   excretion	   rate	   was	   chosen	   as	   for	   the	   kidneys	   and	   urinary	   excretion,	   respectively	  
(assuming	  that	  200	  nm	  particles	  are	  now	  larger	  as	  the	  capillary	  pore	  size	  of	  the	  liver).	  Based	  on	  this	  
assumption,	  the	  translation	  rate	  from	  the	  lung	  to	  the	  blood	  for	  200	  nm	  gold	  particles	  was	  fitted	  with	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the	   in	  vivo	  data	  from	  Kreyling	  et	  al.	   [1]	  using	  the	  same	  approach	  as	  described	  above	  for	  the	  18	  nm	  
AuNP	  (i.e.	  fitting	  the	  lung	  translocation	  rate	  so	  that	  the	  translocation	  fraction	  1	  hour	  post-­‐exposure	  is	  
0.16%,	  which	  was	  measured	   in	  rats).	  Unfortunately,	   there	   is	  only	   indirect	  evidence	  for	  a	  decreased	  
biliary	   excretion	  of	  particles	   above	  150	  nm	  at	   the	  moment	   (e.g.	   [17]	  or	   the	   fact	   that	   the	   reported	  
translocation	  fractions	  by	  Kreyling	  et	  al.	  [1]	  are	  decreasing	  over	  time	  for	  all	  particle	  sizes,	  but	  not	  for	  
200	  nm	  large	  gold	  particles,	  where	  the	  translocation	  fraction	  is	  in	  fact	  increasing	  with	  time).	  However,	  
the	   adjusted	   translocation	   fraction	   for	   200	  nm	  gold	  particles	   fits	  much	  better	   in	   the	   course	  of	   the	  
curve	   as	   compared	   to	   the	   one	   reported	   by	   Kreyling	   et	   al.	   [1]	   (Figure	   S11),	   indicating	   that	   the	  
assumptions	  on	  the	  size	  threshold	  are	  plausible.	  	  
	  
Figure	  S11:	  Size-­‐dependent	  translocation	  kinetics	  of	  various	  sizes	  of	  gold	  particles	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
24	  hours	  after	  intratracheal	  instillation.	  In	  vivo	  data	  from	  female	  Wistar-­‐Kyoto	  rats	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
was	  taken	  from	  Kreyling	  et	  al.	  [1]	  and	  corrected	  for	  biliary	  excretion	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
with	  the	  PBPK	  model	  (for	  200	  nm	  a	  decreased	  biliary	  excretion	  was	  assumed)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(data	  are	  expressed	  as	  mean±SD,	  n=4	  (rats)	  and	  n=1000	  iterations	  (PBPK	  model)).	  
The	   assumptions	   of	   a	   decreased	   biliary	   excretion	   and	   translocation	   to	   the	   liver	   of	   200	   nm	   gold	  
particles	  is	  further	  supported	  by	  the	  modeled	  biodistribution	  with	  the	  modified	  PBPK	  model.	  As	  can	  
be	   seen	   in	   Figure	   S12,	   the	   biodistribution	   can	   be	   well	   predicted	   when	   the	   assumptions	   are	  
considered	   in	   the	   PBPK	  model.	   Except	   for	   the	   kidneys’	   gold	   level,	   the	   gold	   levels	   of	   all	   organs	   fall	  
close	   to	   the	   1:1	   line.	   However,	   it	   should	   be	   noted	   that	   the	   PBPK	   model	   was	   not	   developed	   and	  
validated	   for	   such	   large	  particles.	  Other	   factors,	  which	  are	  not	  considered	   in	   the	  PBPK	  model,	  may	  
also	  influence	  the	  biodistribution	  of	  particles	  above	  150	  nm.	  For	  example,	  Rejman	  et	  al.	  [18]	  reported	  
that	  particles	  below	  200	  nm	  are	  predominantly	  internalized	  via	  clathrin-­‐mediated	  pathways	  by	  non-­‐
phagocytic	   B	   16	   cells,	   while	   particles	   larger	   than	   200	   nm	   are	   to	   a	   higher	   rate	   internalized	   via	  
caveolae-­‐mediated	  pathways.	  Nevertheless,	   it	  seems	  that	  the	  PBPK	  model	  can,	  to	  a	  certain	  degree,	  
also	  be	  used	  for	  particles	  above	  150	  nm,	  but	  it	  should	  be	  kept	  in	  mind	  that	  the	  predictive	  capability	  
of	  the	  PBPK	  model	  above	  this	  size	  limit	  has	  not	  been	  properly	  evaluated	  yet.	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Figure	  S12:	  Comparison	  of	  the	  PBPK	  model	  to	  biokinetic	  data	  of	  female	  Wistar-­‐Kyoto	  rats	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
of	  different	  time	  points	  after	  intratracheal	  instillation	  of	  200	  nm	  large	  gold	  particles	  [1]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(only	  organs	  where	  the	  gold	  levels	  in	  all	  rats	  were	  above	  the	  LOD	  are	  depicted;	  data	  are	  expressed	  as	  
mean±SD,	  n=4	  (rats)	  and	  n=1000	  iterations	  (PBPK	  model)).	  
In	  Figure	  S13,	  the	  biodistribution	  of	  AuNP	  in	  mice	  was	  predicted	  by	  using	  the	  exposure	  conditions	  of	  
Schleh	  et	  al.	  [2]	  as	  input	  parameters	  for	  our	  PBPK	  model.	  
	  
Figure	  S13:	  Biodistribution	  of	  20	  nm	  AuNP	  in	  mice	  immediately	  after	  two	  hours	  of	  inhalation	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
exposure	  (total	  deposition	  3.31	  ng/cm2)	  as	  predicted	  by	  the	  PBPK	  model.	  The	  translocation	  fraction	  
(1.2%,	  adjusted	  for	  biliary	  excretion:	  1.42%)	  was	  fitted	  to	  match	  the	  in	  vivo	  data	  from	  Schleh	  et	  al.	  [2]	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(data	  are	  expressed	  as	  mean±SD,	  n=1000	  iterations).	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4.3. PBPK	  model	  Parameters,	  Equations	  and	  Assumptions	  
4.3.1. Physiological	  Parameters	  
The	   physiological	   parameters	   for	  mice	   and	   rats	   are	   summarized	   in	   Table	   S3.	   For	   the	  Monte	   Carlo	  
simulation	  the	  blood	  flow	  to	  the	  organs	  was	  normalized	  to	  the	  average	  organ	  weight.	  
	  
Table	  S3:	  Physiological	  parameters	  for	  weight	  and	  blood	  flow	  (mean±SD)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
of	  organs	  in	  %	  of	  total	  body	  weight	  and	  %	  of	  cardiac	  output,	  respectively.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
If	  not	  indicated	  otherwise,	  parameter	  values	  were	  taken	  from	  Brown	  et	  al.	  [19]	  
Weight [%] Blood Flow [%] Weight [%] Blood Flow [%]
Liver 5.49 ± 1.32 16.10 ± 0.20 3.66 ± 0.65 18.30 ± 2.50
Kidneys 1.67 ± 0.17 9.10 ± 2.90 0.73 ± 0.11 14.10 ± 1.90
Spleen 0.35 ± 0.16 1.13 ± 0.34a,b 0.20 ± 0.05 0.85 ± 0.26a,b
Heart 0.50 ± 0.07 6.60 ± 0.90 0.33 ± 0.04 5.10 ± 0.10
Brain 1.65 ± 0.26 3.30 ± 0.30 0.57 ± 0.14 2.00 ± 0.30
Lung 0.73 ± 0.08 1.92 ± 0.87c 0.50 ± 0.09 2.10 ± 0.40




a	  D avies 	  and	  Morris 	  (1993)
b	  No 	  data	  fo r	  the	  s tandard	  deviation	  is 	  available.	  H ence,	  the	  s tandard	  deviation	  was 	  es timated	  bas ed	  on	  the	  s tandard	  deviation	  from	  the	  o ther	  o rgans .
c	  S to tt	  et	  al.	  (1983)
d	  R iches 	  et	  al.	  (1973)












4.3.2. Compound-­‐dependent	  Parameters	  
The	  organs	  were	  grouped	  according	  to	  their	  CT	  and	  in	  total,	  four	  CT	  groups	  were	  identified	  (adapted	  
from	  Sarin	  [16],	  see	  also	  Table	  S4):	  
• CT1:	  	   non-­‐sinusoidal	  non-­‐fenestrated	  blood	  capillary	  type	  (i.e.	  brain,	  heart,	  lung),	  
• CT2:	  	   non-­‐sinusoidal	  fenestrated	  blood	  capillary	  type	  (i.e.	  kidneys),	  	  
• CT3:	  	   sinusoidal	  blood	  capillary	  type	  with	  pores	  larger	  than	  15	  nm	  (i.e.	  liver,	  spleen),	  	  
• CT4:	  	   the	   “Remainder”	   compartment,	   which	   represents	   all	   tissues	   and	   organs	   that	   are	   not	  
covered	  by	  any	  other	  compartment,	  hence,	  could	  not	  be	  assigned	  to	  a	  specific	  CT	  group.	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Table	  S4:	  Classification	  of	  blood	  capillary	  type	  and	  the	  physiological	  upper	  limit	  of	  pore	  size	  according	  to	  
Sarin	  [16]	  as	  used	  for	  defining	  the	  capillary	  wall	  type	  groups	  (The	  CT4	  describes	  the	  permeability	  of	  the	  
“Remainder”	  compartment	  and,	  hence	  covers	  various	  capillary	  types)	  
Capillary type Sub-Type Physiological upper limit of pore size Representative tissue
Model 
Compartments
with tight junctions <1nm








Skin, Testis, Kidney Peritubular, 
Intestinal Mucosa










Splenic red pulp venous blood 
capillary














open fenestrae Liver LiverCT3
CT3
	  
The	  compound-­‐dependent	  parameters	  that	  describe	  the	  distribution	  and	  excretion,	  and	  absorption	  
of	  AuNP	  are	  summarized	  in	  Table	  S5	  and	  Table	  S6,	  respectively.	  The	  listed	  translocation	  constants	  for	  
NPs	   (CT1-­‐4,	   biliary	   and	   urinary	   excretion)	   were	   directly	   taken	   from	   our	   recently	   presented	   PBPK	  
model	   for	   TiO2	   NPs	   [10].	   The	   translocation	   rate	   from	   the	   organs	   to	   the	   blood	   circulation,	   the	  
pulmonary	  absorption	  rate	  and	  the	  lung	  storage	  rate	  were	  fitted	  to	  match	  the	  in	  vivo	  data	  of	  the	  18	  
nm	  AuNP	  from	  Kreyling	  et	  al.	  [1].	  The	  pulmonary	   absorption	   rates	  of	   the	  other	  particle	   sizes	  
were	  fitted	  with	  the	  according	  in	  vivo	  data	  (Kreyling	  et	  al.:	  1.4,	  2.8,	  5,	  80	  and	  200	  nm;	  Schleh	  
et	  al.:	  20	  nm),	  which	  is	  discussed	  in	  more	  detail	  in	  the	  main	  text.	  For	  more	  information	  on	  the	  
model	   methodology	   and	   model	   parameterization	   see	   the	   discussion	   above	   (“PBPK	   Model	  
Methodology	  and	  Parameterization”).	  
Table	  S5:	  Compound-­‐dependent	  parameters	  for	  the	  distribution	  and	  excretion	  of	  AuNP	  (mean±SD).	  
Acronym Value [10-4] Unit
Nanoparticulate translocation constantsa btrans_constant_organ
CT1 0.622 ± 0.194 -
CT2b 4.97 ± 2.31 -
CT3 9.95 ± 2.74 -
CT4 34.2 ± 4.09 -
Biliary excretion 61.3 ± 3.28 -
Urinary excretionb 1.55 ± 0.0830 -
Translocation rate from the organ to the bloodc ktrans_organ_blood 33.0 ± 11.3 min-1
a Which w as used for the calculation of the translocation rate [min-1] of NPs from the blood to the organs/excrements - see Equation S1
b For the 200 nm particles the CT2 translocation constant and urinary excretion constant w ere used to determine the translocation rate from the blood to the liver 
      and feces, respictively. This w as done according to the idea of the PBPK model that partiles of this size cannot pass the capillary w all of the liver as easy 
      as smaller particles due to the pore size of the capillary w all.
c Decreased by a factor of 10 for the brain compartment to consider the blood-brain barrier
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Table	  S6:	  Compound-­‐dependent	  parameters	  for	  the	  absorption	  of	  AuNP	  (mean±SD).	  
Acronym Value [10-4] Unit
Translocation rate from the lung deposition to the blood ktrans_lung_blood 
1.4 nm 76.7 ± 7.38 min-1
2.8 nm 36.4 ± 3.50 min-1
5 nm 2.29 ± 0.220 min-1
18 nm 1.30 ± 0.125 min-1
80 nm 0.631 ± 0.0606 min-1
200 nm 0.568 ± 0.0546 min-1
Schleh et al.  [2] 20 nm 5.93 ± 0.570 min-1
Storage rate of the deposited gold in the lung kstorage_lung 300 ± 120 min-1




4.3.3. Model	  Assumptions	  
Table	  S7:	  Summary	  of	  the	  assumptions	  made	  for	  the	  AuNP	  PBPK	  model	  
General	  
• The	  mixing	  of	  nanoparticles	   in	  all	   compartments	   is	   instantaneous	  and	  
complete.	  
• First-­‐order	  kinetics	  is	  describing	  reasonably	  well	  the	  processes	  in	  vivo.	  
Distribution	  
• Blood	  flow	  is	  non-­‐pulsatile	  and	  constant.	  
• Distribution	   of	   nanoparticles	   in	   the	   blood	   stream	   is	   size-­‐independent	  
and	  the	  particles	  do	  not	  alter	  the	  blood	  flow	  rate.	  
• Endocytosis	   processes	   are	   size-­‐independent	   (which	   does	   not	   hold	   for	  
the	  absorption	  of	  AuNP	  to	  the	  blood	  circulation	  in	  the	  lung).	  
• The	  organ	  uptake	  of	  AuNP	  via	   the	  capillary	  wall	   is	  proportional	   to	  the	  
amount	  of	  gold	  that	  passes	  the	  capillary	  walls.	  
• For	  AuNP	   the	   transport	   efficiency	   through	   the	   capillary	  wall	   is	   similar	  
between	  mice	  and	  rats.	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4.3.4. Model	  Equations	  
Table	  S8:	  Model	  equations	  of	  the	  AuNP	  PBPK	  model	  (for	  mice	  and	  rats).	  The	  model	  parameters	  and	  rates	  used	  are	  listed	  in	  Table	  S3-­‐S6	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(“A”	  denotes	  the	  amount	  of	  gold	  in	  the	  corresponding	  compartment)	  
Translocation	  rate	  from	  the	  blood	  to	  the	  organsa:	   𝑘!"#$%_!"##$_!"#$%   =   b!"#$%_!"#$%&#%_!"#$% ∗   𝑄!"#$%_!"##$𝑉!"##$ 	  
Absorptionb	  
Deposition	  in	  the	  lung	   d𝐴!"#$%&'&$(_!"#$d𝑡 =   𝑚!"#$%&'&$(!   −   𝑘!"#$%&'_!"#$   ∗   𝐴!"#$%&'&$(_!"#$   −   𝑚!"#$%&'($)	  
Absorption	  to	  the	  blood	   𝑚!"#$%&'($) =     𝑘!!"#$_!"#$_!"##$   ∗   𝐴!"#$%&'&$(_!"#$   	  
(Temporary)	  Storage	  in	  the	  lungd	   d𝐴!"#$%&!"#$_!"#$%&'_!"#$d𝑡 =   𝑘!"#$%&'_!"#$   ∗   𝐴!"#$%&'&$(_!"#$	  
Distribution	  
Blood	  compartment:	  
d𝐴!"##$d𝑡 =   𝑚!"#$%&'($)   +    k!!"#$_!"#$%_!"##$   ∗   𝐴!"#$%!"#$%&!     −    𝑘!!"#$_!"##$_!"#$%   ∗   𝐴!"##$!"#$%&! 	  
Organe	  compartment:	   d𝐴!"#$%d𝑡 =   𝑘!!"#$_!"##$_!"#$%   ∗   𝐴!"##$   –   k!!"#$_!"#$%_!"##$   ∗   𝐴!"#$%	  
Excretion	  
Biliary	  excretion:	   d𝐴!"#"$%&_!"#$!%&'(d𝑡 =   𝑘!!"#$_!"##$_!"#$%!!"#"$%&   ∗   𝐴!"##$       	  
Urinary	  excretion:	  
d𝐴!"#$%"&_!"#$!%&'(d𝑡 =   𝑘!!"#$_!"##$_!"#$%!!"#$%"&   ∗   𝐴!"##$	  
a	  Organ:	  brain,	  excrements	  (biliary	  and	  urinary	  excretion),	  heart,	  kidneys,	  liver,	  lung,	  remainder	  and	  spleen	  compartment	  
b	  Absorption:	  Inhalation	  and	  instillation	  
c	  ṁdepsosition:	  for	  Kreyling	  et	  al.	  [1]	  –	  instillation:	  deposition	  of	  all	  gold	  within	  one	  minute;	  for	  Schleh	  et	  al.	  [2]	  	  –	  inhalation:	  deposition	  13.5	  ng/min	  for	  two	  hours	  (in	  total	  1.7	  µg	  or	  3.31	  ng/cm
2)	  
d	  The	  long-­‐term	  behavior	  of	  this	  “stored”	  gold	  is	  unknown.	  The	  available	  in	  vivo	  data	  from	  Kreyling	  et	  al.	  [1]	  is	  only	  available	  for	  the	  first	  24	  hours	  after	  exposure	  (see	  also	  main	  text)	  
e	  Organ:	  brain,	  heart,	  kidneys,	  liver,	  lung,	  remainder	  and	  spleen	  compartment	  
Bachler	  et	  al.	  	   	   Pulmonary	  translocation	  of	  gold	  NPs	  
S20	  
5. References	  
1.	   Kreyling	  WG,	  Hirn	  S,	  Moller	  W,	  Schleh	  C,	  Wenk	  A,	  Celik	  G,	  Lipka	  J,	  Schaffler	  M,	  Haberl	  N,	  Johnston	  BD,	  
et	  al:	  Air-­‐blood	  barrier	  translocation	  of	  tracheally	   instilled	  gold	  nanoparticles	   inversely	  depends	  on	  
particle	  size.	  ACS	  Nano	  2014,	  8:222-­‐233.	  
2.	   Schleh	  C,	  Holzwarth	  U,	  Hirn	   S,	  Wenk	  A,	   Simonelli	   F,	   Schaffler	  M,	  Moller	  W,	  Gibson	  N,	   Kreyling	  WG:	  
Biodistribution	   of	   inhaled	   gold	   nanoparticles	   in	   mice	   and	   the	   influence	   of	   surfactant	   protein	   D.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
J	  Aerosol	  Med	  Pulm	  Drug	  Deliv	  2013,	  26:24-­‐30.	  
3.	   Masereel	   B,	   Dinguizli	   M,	   Bouzin	   C,	   Moniotte	   N,	   Feron	   O,	   Gallez	   B,	   Borght	   TV,	  Michiels	   C,	   Lucas	   S:	  
Antibody	   immobilization	   on	   gold	   nanoparticles	   coated	   layer-­‐by-­‐layer	   with	   polyelectrolytes.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
J	  Nanopart	  Res	  2011,	  13:1573-­‐1580.	  
4.	   Kelly	   JJ,	   Moore	   TM,	   Babal	   P,	   Diwan	   AH,	   Stevens	   T,	   Thompson	   WJ:	   Pulmonary	   microvascular	   and	  
macrovascular	  endothelial	  cells:	  differential	  regulation	  of	  Ca2+	  and	  permeability.	  Am	  J	  Physiol-­‐Lung	  C	  
1998,	  274:L810-­‐L819.	  
5.	   Bouwmeester	  H,	  Poortman	  J,	  Peters	  RJ,	  Wijma	  E,	  Kramer	  E,	  Makama	  S,	  Puspitaninganindita	  K,	  Marvin	  
HJ,	   Peijnenburg	   AA,	   Hendriksen	   PJ:	   Characterization	   of	   translocation	   of	   silver	   nanoparticles	   and	  
effects	  on	  whole-­‐genome	  gene	  expression	  using	  an	   in	  vitro	   intestinal	  epithelium	  coculture	  model.	  
ACS	  Nano	  2011,	  5:4091-­‐4103.	  
6.	   Elbert	  KJ,	  Schafer	  UF,	  Schafers	  HJ,	  Kim	  KJ,	  Lee	  VHL,	  Lehr	  CM:	  Monolayers	  of	  human	  alveolar	  epithelial	  
cells	  in	  primary	  culture	  for	  pulmonary	  absorption	  and	  transport	  studies.	  Pharm	  Res	  1999,	  16:601-­‐608.	  
7.	   Salomon	  JJ,	  Muchitsch	  VE,	  Gausterer	  JC,	  Schwagerus	  E,	  Huwer	  H,	  Daum	  N,	  Lehr	  CM,	  Ehrhardt	  C:	  The	  
Cell	  Line	  NCl-­‐H441	  Is	  a	  Useful	   in	  Vitro	  Model	  for	  Transport	  Studies	  of	  Human	  Distal	  Lung	  Epithelial	  
Barrier.	  Mol	  Pharm	  2014,	  11:995-­‐1006.	  
8.	   Sakagami	  M:	  In	  vivo,	  in	  vitro	  and	  ex	  vivo	  models	  to	  assess	  pulmonary	  absorption	  and	  disposition	  of	  
inhaled	  therapeutics	  for	  systemic	  delivery.	  Adv	  Drug	  Delivery	  Rev	  2006,	  58:1030-­‐1060.	  
9.	   Mahida	   YR,	  Makh	   S,	   Hyde	   S,	   Gray	   T,	   Borriello	   SP:	  Effect	   of	   Clostridium	   difficile	   toxin	   A	   on	   human	  
intestinal	  epithelial	  cells:	  Induction	  of	  interleukin	  8	  production	  and	  apoptosis	  after	  cell	  detachment.	  
Gut	  1996,	  38:337-­‐347.	  
10.	   Bachler	   G,	   von	   Goetz	   N,	   Hungerbuhler	   K:	   Using	   physiologically	   based	   pharmacokinetic	   (PBPK)	  
modeling	  for	  dietary	  risk	  assessment	  of	  titanium	  dioxide	  (TiO2)	  nanoparticles.	  Nanotoxicology	  2014,	  
early	  online.	  
11.	   Bachler	  G,	   von	  Goetz	  N,	  Hungerbuhler	   K:	  A	   physiologically	   based	   pharmacokinetic	  model	   for	   ionic	  
silver	  and	  silver	  nanoparticles.	  Int	  J	  Nanomedicine	  2013,	  8:3365-­‐3382.	  
12.	   Schmidt	  J,	  Vogelsberger	  W:	  Dissolution	  kinetics	  of	  titanium	  dioxide	  nanoparticles:	  the	  observation	  of	  
an	  unusual	  kinetic	  size	  effect.	  J	  Phys	  Chem	  B	  2006,	  110:3955-­‐3963.	  
13.	   Landsiedel	   R,	   Fabian	   E,	   Ma-­‐Hock	   L,	   Wohlleben	   W,	   Wiench	   K,	   Oesch	   F,	   van	   Ravenzwaay	   B:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Toxico-­‐/biokinetics	  of	  nanomaterials.	  Arch	  Toxicol	  2012,	  86:1021-­‐1060.	  
14.	   Goppert	   TM,	   Muller	   RH:	   Polysorbate-­‐stabilized	   solid	   lipid	   nanoparticles	   as	   colloidal	   carriers	   for	  
intravenous	   targeting	   of	   drugs	   to	   the	   brain:	   Comparison	   of	   plasma	  protein	   adsorption	   patterns.	   J	  
Drug	  Target	  2005,	  13:179-­‐187.	  
15.	   Choi	  HS,	  Liu	  W,	  Misra	  P,	  Tanaka	  E,	  Zimmer	  JP,	  Itty	  Ipe	  B,	  Bawendi	  MG,	  Frangioni	  JV:	  Renal	  clearance	  of	  
quantum	  dots.	  Nat	  Biotechnol	  2007,	  25:1165-­‐1170.	  
16.	   Sarin	   H:	   Physiologic	   upper	   limits	   of	   pore	   size	   of	   different	   blood	   capillary	   types	   and	   another	  
perspective	  on	  the	  dual	  pore	  theory	  of	  microvascular	  permeability.	  J	  Angiogenes	  Res	  2010,	  2:1-­‐14.	  
17.	   Hirn	  S,	  Semmler-­‐Behnke	  M,	  Schleh	  C,	  Wenk	  A,	  Lipka	  J,	  Schaffler	  M,	  Takenaka	  S,	  Moller	  W,	  Schmid	  G,	  
Simon	  U,	  Kreyling	  WG:	  Particle	  size-­‐dependent	  and	  surface	  charge-­‐dependent	  biodistribution	  of	  gold	  
nanoparticles	  after	  intravenous	  administration.	  Eur	  J	  Pharm	  Biopharm	  2011,	  77:407-­‐416.	  
18.	   Rejman	   J,	   Oberle	   V,	   Zuhorn	   IS,	   Hoekstra	   D:	   Size-­‐dependent	   internalization	   of	   particles	   via	   the	  
pathways	  of	  clathrin-­‐	  and	  caveolae-­‐mediated	  endocytosis.	  Biochem	  J	  2004,	  377:159-­‐169.	  
19.	   Brown	   RP,	   Delp	   MD,	   Lindstedt	   SL,	   Rhomberg	   LR,	   Beliles	   RP:	   Physiological	   parameter	   values	   for	  
physiologically	  based	  pharmacokinetic	  models.	  Toxicol	  Ind	  Health	  1997,	  13:407-­‐484.	  
20.	   Davies	   B,	  Morris	   T:	  Physiological	   parameters	   in	   laboratory	   animals	   and	   humans.	  Pharm	  Res	  1993,	  
10:1093-­‐1095.	  
21.	   Riches	  AC,	  Sharp	  JG,	  Thomas	  DB,	  Smith	  SV:	  Blood	  volume	  determination	  in	  the	  mouse.	  J	  Physiol	  1973,	  
228:279-­‐284.	  
22.	   Lee	  HB,	  Blaufox	  MD:	  Blood	  volume	  in	  the	  rat.	  J	  Nucl	  Med	  1985,	  26:72-­‐76.	  
Bachler	  et	  al.	  	   	   Pulmonary	  translocation	  of	  gold	  NPs	  
S21	  
23.	   Stott	  WT,	  Dryzga	  MD,	  Ramsey	  JC:	  Blood-­‐flow	  distribution	   in	   the	  mouse.	  J	  Appl	  Toxicol	  1983,	  3:310-­‐
312.	  
